Illumina Announces Expansion of TruSight Oncology Portfolio
Illumina Announces Expansion of TruSight Oncology Portfolio
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology
最新的腫瘤全面基因組分析解決方案將在分子病理學會年會上介紹
Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling
客戶主導的研究和會議演講將提供有關腫瘤分析的最新證據和教育
SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. Detailed plans for the product will be shared November 21 in a spotlight presentation at the annual meeting of the Association of Molecular Pathology (AMP) in Vancouver, British Columbia.
聖地亞哥，2024年11月19日 /美通社/ -- illumina公司（納斯達克：ILMN），作爲全球領先的DNA測序和基於芯片的技術公司，今天宣佈將發佈TruSight Oncology 500 v2（電訊首科500 v2），這是其旗艦抗癌醫藥檢測試劑的新版本，以實現全面的基因組分析（CGP）。該檢測試劑目前正在開發中，全球發佈計劃在2025年年中進行。有關該產品的詳細計劃將於11月21日在位於不列顛哥倫比亞省溫哥華的分子病理學會（AMP）年會上進行重點演講。
譯文內容由第三人軟體翻譯。
